1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Senate To Consider User Fee Bill Soon, As Hopes For BCRA Passage With Device Tax Repeal Fade

 
• By Sue Darcey

Sen. Lamar Alexander, R-Tenn., has placed the user fee FDA Reauthorization Act on the Senate legislative calendar, and is just waiting on a nod from the chamber leadership to bring it up for consideration on the floor. On July 18, after successfully passing an Agriculture/FDA funding bill for 2018 onto the full committee, Ag/FDA Subcommittee Chair John Hoeven, R-N.D., characterized FDARA as non-controversial and ripe for passage. Meanwhile, industries' hopes for device tax repeal as part of legislation repealing the Affordable Care Act are fading away.

Sen. Lamar Alexander, R-Tenn., placed the House-passed device and drug user fee bill, the FDA Reauthorization Act, on the Senate's legislative calendar July 17, which means the bill could be brought up for consideration sometime this week.

Also, the second collapse of support for an Affordable Care Act repeal and replacement bill (Better Care Reconciliation Act), including...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

MDUFA VI Talks Begin with Familiar Priorities: Innovation, Transparency, Safety

 
• By Elizabeth Orr

At an Aug. 4 public meeting on MDUFA VI, FDA officials, industry representatives, and patient advocates outlined their priorities for the next user fee agreement, highlighting goals such as improved transparency, streamlined reviews, enhanced safety measures, and greater patient involvement.

Bipartisan Senate Bill Would Give Patients ‘True Price Tag’ Prior To Care

 
• By Brian Bossetta

Pending legislation seeks to address what the sponsors argue is a lack of transparency in medical billing. If enacted, the bill would provide patients with the costs of procedures and medications before receiving them. A data collection expert discusses what the bill could mean for patients.

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 
• By Natasha Barrow

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.

House Bill Calls For ‘Non-Flushable’ Label On Personal Wipes

 
• By Eileen Francis

The US House of Representatives passes legislation requiring manufacturers of non-flushable wet wipes to label products as ‘non-flushable," a move endorsed by the Personal Care Products Council.

More from Policy & Regulation

Brazil’s Medtechs Look To Solutions After 50% US Tariff Hit Amid ‘Scenario Of Uncertainty’

 
• By Bernard Murphy

Hopes that last-minute negotiations might exempt Brazil’s $300m medtech exports from the latest round of US tariffs have been dashed, leaving the industry braced for further market instability that countermeasures could trigger.

Survey Reveals Gaps In Medtech Compliance Processes

 
• By Elizabeth Orr

Medical device firms often have serious compliance gaps, a recent Veeva MedTech survey found. Only 50% of the companies surveyed are confident in their global registration data, with 70% reporting inconsistencies during audits. The report recommends automation and better data governance.

Environmental Group Questions FDA’s Stance On PFAS In Medical Devices

 
• By Brian Bossetta

The US FDA says PFAS used in medical devices are safe and that there’s no reason to restrict them in device production. An environmental group finds the agency’s assertion questionable.